Skip to Content

Gevokizumab Approval Status

FDA Approved: No
Generic name: gevokizumab
Company: XOMA Corporation
Treatment for: Uveitis

Gevokizumab is a potent monoclonal antibody in development for the treatment of non-infectious uveitis.

Development Status and FDA Approval Process for gevokizumab

DateArticle
Mar  4, 2014XOMA Provides Update on Gevokizumab Proof-of-Concept Program
Feb 24, 2014XOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum
Aug 24, 2012XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide